This indefinite delivery contract was awarded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $13.3M contract, titled the "Gene Therapy Resource Program (GTRP)," aims to support translational gene therapy research by providing resources and services from three core laboratories: Pharmacology and Toxicology, Preclinical Vector, and a Clinical Coordinating Center.
The contract has a total period of performance through June 18, 2025 and does not utilize any set-aside designations. Multiple task orders have been issued to Lovelace Biomedical, valued at over $4.6M cumulatively, for specific GTRP support services such as pharmacology/toxicology studies, scientific project support, and core administrative activities. Lovelace Biomedical has a proven track record as a prime contractor for federal agencies like NIH, DoD, and HHS, providing a wide range of preclinical research services including animal studies, analytical testing, and disease model development.
Generated 6/15/24, 9:12 AM